KR20230131236A - 항-pd-l1 항체 및 이의 융합 단백질 - Google Patents

항-pd-l1 항체 및 이의 융합 단백질 Download PDF

Info

Publication number
KR20230131236A
KR20230131236A KR1020237026702A KR20237026702A KR20230131236A KR 20230131236 A KR20230131236 A KR 20230131236A KR 1020237026702 A KR1020237026702 A KR 1020237026702A KR 20237026702 A KR20237026702 A KR 20237026702A KR 20230131236 A KR20230131236 A KR 20230131236A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
cdr
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237026702A
Other languages
English (en)
Korean (ko)
Inventor
리 펑
제니 체
리후이 수
Original Assignee
팔레온 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팔레온 파마슈티칼스 인크. filed Critical 팔레온 파마슈티칼스 인크.
Publication of KR20230131236A publication Critical patent/KR20230131236A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237026702A 2021-01-06 2022-01-06 항-pd-l1 항체 및 이의 융합 단백질 Pending KR20230131236A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
US63/134,412 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (1)

Publication Number Publication Date
KR20230131236A true KR20230131236A (ko) 2023-09-12

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026702A Pending KR20230131236A (ko) 2021-01-06 2022-01-06 항-pd-l1 항체 및 이의 융합 단백질

Country Status (10)

Country Link
US (1) US20240067729A1 (https=)
EP (1) EP4274614A4 (https=)
JP (1) JP2024501771A (https=)
KR (1) KR20230131236A (https=)
CN (1) CN116829188A (https=)
AU (1) AU2022206264A1 (https=)
CA (1) CA3173557A1 (https=)
IL (1) IL304190A (https=)
MX (1) MX2023008028A (https=)
WO (1) WO2022150521A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006492A2 (en) * 2020-07-03 2022-01-06 Palleon Pharmaceuticals Inc. Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
WO2022150516A1 (en) * 2021-01-06 2022-07-14 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148763A (en) * 2006-03-10 2013-05-31 Wyeth Corp Anti-5t4 antibodies and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA2904969C (en) * 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016160792A1 (en) * 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
KR102914621B1 (ko) * 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
WO2022150521A1 (en) 2022-07-14
IL304190A (en) 2023-09-01
AU2022206264A1 (en) 2023-07-20
CA3173557A1 (en) 2022-07-14
JP2024501771A (ja) 2024-01-15
MX2023008028A (es) 2023-08-14
US20240067729A1 (en) 2024-02-29
EP4274614A4 (en) 2025-06-18
CN116829188A (zh) 2023-09-29
EP4274614A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
KR102914621B1 (ko) 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
CN109311973B (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
CN109705218B (zh) Asgpr抗体及其用途
CN109071652B (zh) 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
KR102665542B1 (ko) T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
KR102648966B1 (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
CN107207604B (zh) 抗alk2抗体
TWI688572B (zh) 包含dr5-結合結構域的多價分子
KR20230131236A (ko) 항-pd-l1 항체 및 이의 융합 단백질
CN110382542B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
KR20220032576A (ko) 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
TW201704266A (zh) 雙特異性抗體
KR20230034320A (ko) 프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법
KR20230138473A (ko) 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
KR20220034812A (ko) 재조합 시알리다제 및 그의 사용 방법
KR20230142722A (ko) 시알리다제-pd-1-항체 융합 단백질들 및 이의 사용방법
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer
HK40007646A (en) Asgpr antibodies and uses thereof
HK40007646B (en) Asgpr antibodies and uses thereof
HK40015870A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40002146A (en) Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230804

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250106

Comment text: Request for Examination of Application